Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

  • Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521
     
  • nr-axSpA is the fourth EU indication for Cosentyx, providing patients in Europe with a first-in-class treatment that addresses the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US2
     
  • PREVENT is …
/by
Sandoz launches once-daily generic tacrolimus for transplant patients in Europe
  • Sandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titration
  • Sandoz 2 mg slow-release capsule offers simplified once-daily treatment protocol that may reduce a patient’s daily pill burden1
  • Launch builds on Sandoz experience with Adoport® — #1 twice-daily generic tacrolimus in Europe2

Holzkirchen, June 4, 2020 – Sandoz today announced the launch of once-daily generic tacrolimus capsules known as Dailiport® in …

/by